Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency.
Annaswamy RajiZhi Jin XuRaymond L H LamEdward A O'NeillKeith D KaufmanSamuel S EngelPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2020)
In patients ≥ 65 years of age with T2D and mild renal insufficiency with inadequate glycemic control on metformin ± sulfonylurea, treatment with sitagliptin for 24 weeks resulted in improvement in HbA1c relative to treatment with dapagliflozin that is consistent with that previously observed in the overall population. Both treatments were generally well tolerated.